TY - JOUR
T1 - Gout and risk of non-alcoholic fatty liver disease
AU - Kuo, C. F.
AU - Yu, K. H.
AU - Luo, S. F.
AU - Chiu, C. T.
AU - Ko, Y. S.
AU - Hwang, J. S.
AU - Tseng, W. Y.
AU - Chang, H. C.
AU - Chen, H. W.
AU - See, L. C.
PY - 2010/11
Y1 - 2010/11
N2 - Objectives: To investigate the association between gout and non-alcoholic fatty liver disease (NAFLD). Methods: The study subjects were participants in a health-screening programme at Chang Gung Memorial Hospital from 2000 to 2006. Subjects were classified into eight groups based on serum urate (SU) level and gout status (≤ 4.9, 5.06.9, 7.08.9, and ≥ 9.0 mgdL, without and with gout). The association between gout and NAFLD was assessed by multiple logistic regression. Results: Among a total of 54 325 subjects, 1930 (3.6) had gout and 6169 (11.3) had NAFLD. The prevalence of NAFLD was significantly higher in subjects with gout (23.1, n 445) than in those without gout (10.9, n 5724, p < 0.001). Among subjects with NAFLD, the severity of NAFLD was higher in gout patients. Gout was associated with an increased risk for NAFLD [odds ratio (OR) 1.42, 95 confidence interval (CI) 1.251.60, p < 0.001], after adjustment for age, sex, presence of metabolic syndrome, and low estimated glomerular filtration rate (eGFR). With SU ≤ 4.9 mgdL in the absence of gout as reference, the ORs (95 CI) for NAFLD, after adjustment for age, sex, presence of metabolic syndrome, and low eGFR, were, respectively, 2.16 (1.942.41), 3.98 (3.554.46), and 5.99 (5.196.90) for SU levels 24 in those without gout and 2.61 (1.394.91), 2.87 (2.044.04), 4.53 (3.705.56), and 6.31 (5.127.77) for SU levels 14 in those with gout. Conclusions: There was an independent association between gout and the risk for NAFLD. In addition, there was a doseresponse relationship between SU and NAFLD in subjects with and without gout.
AB - Objectives: To investigate the association between gout and non-alcoholic fatty liver disease (NAFLD). Methods: The study subjects were participants in a health-screening programme at Chang Gung Memorial Hospital from 2000 to 2006. Subjects were classified into eight groups based on serum urate (SU) level and gout status (≤ 4.9, 5.06.9, 7.08.9, and ≥ 9.0 mgdL, without and with gout). The association between gout and NAFLD was assessed by multiple logistic regression. Results: Among a total of 54 325 subjects, 1930 (3.6) had gout and 6169 (11.3) had NAFLD. The prevalence of NAFLD was significantly higher in subjects with gout (23.1, n 445) than in those without gout (10.9, n 5724, p < 0.001). Among subjects with NAFLD, the severity of NAFLD was higher in gout patients. Gout was associated with an increased risk for NAFLD [odds ratio (OR) 1.42, 95 confidence interval (CI) 1.251.60, p < 0.001], after adjustment for age, sex, presence of metabolic syndrome, and low estimated glomerular filtration rate (eGFR). With SU ≤ 4.9 mgdL in the absence of gout as reference, the ORs (95 CI) for NAFLD, after adjustment for age, sex, presence of metabolic syndrome, and low eGFR, were, respectively, 2.16 (1.942.41), 3.98 (3.554.46), and 5.99 (5.196.90) for SU levels 24 in those without gout and 2.61 (1.394.91), 2.87 (2.044.04), 4.53 (3.705.56), and 6.31 (5.127.77) for SU levels 14 in those with gout. Conclusions: There was an independent association between gout and the risk for NAFLD. In addition, there was a doseresponse relationship between SU and NAFLD in subjects with and without gout.
UR - https://www.scopus.com/pages/publications/78649710412
U2 - 10.3109/03009741003742797
DO - 10.3109/03009741003742797
M3 - 文章
C2 - 20560813
AN - SCOPUS:78649710412
SN - 0300-9742
VL - 39
SP - 466
EP - 471
JO - Scandinavian Journal of Rheumatology
JF - Scandinavian Journal of Rheumatology
IS - 6
ER -